Poly(ADP-ribosylation) and Neoplastic Transformation: Effect of PARP Inhibitors

E-ISSN： 1873-4316|14|5|524-536

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.14, Iss.5, 2013-06, pp. : 524-536

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New inhibitors of poly(ADP-ribose) polymerase (PARP)

By Peukert Stefan Schwahn Uwe

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 11, 2004-11 ,pp. : 1531-1551

Informa Healthcare

Access to resources Recommend Favorite

Current Overview on the Usage of Poly(ADP-ribose)polymerase (PARP) Inhibitors in Treating Cancer

Clinical Cancer Drugs, Vol. 1, Iss. 2, 2014-01 ,pp. : 127-148

Bentham Science Publishers

Access to resources Recommend Favorite

Current Overview on the Usage of Poly(ADP-ribose)polymerase (PARP) Inhibitors in Treating Cancer

Clinical Cancer Drugs, Vol. 1, Iss. 2, 2014-05 ,pp. : 127-148

Bentham Science Publishers

Access to resources Recommend Favorite

Poly(ADP-Ribose) Polymerase Inhibitors

Current Medicinal Chemistry, Vol. 10, Iss. 4, 2003-01 ,pp. : 321-340

Bentham Science Publishers

Access to resources Recommend Favorite

Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 11, Iss. 4, 2011-12 ,pp. : 326-333

Bentham Science Publishers

Access to resources Recommend Favorite